Skip to content

Evaluation of 3D Rotational Angiography After EVAR

Evaluation of 3D Rotational Angiography After EVAR

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02894749
Acronym
EVAR
Enrollment
427
Registered
2016-09-09
Start date
2015-08-01
Completion date
2017-01-06
Last updated
2026-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Aneurysm, Abdominal, Radiation Burn

Keywords

hybrid rooms, cone-beam computed tomography

Brief summary

This is a randomized prospective monocentric study to evaluate the benefits of a 3D rotational acquisition (3DRA) to assess technical success after treatment of infra-renal aneurysm with bifurcated endograft. Patients will be randomized between the standard strategy (2D angiography at the end of the procedure and angioCT-scan before discharge) and the new strategy (3DRA at the end of the procedure). Expected findings are a reduction of radiation exposure and contrast medium used during the hospital stay, with a similar resolution between angioCT-scan and 3DRA to depict the main complications after EVAR (occlusion, kinking, endoleak). Furthermore, any complication depicted after 3DRA group could benefit from an additional procedure during the same operating time, and therefore avoid a second intervention for the patient.

Interventions

RADIATION3D rotational angiography (3DRA)

3DRA allows CT-like reconstructions. It requires less X-rays and contrast medium than standard angioCT-scan. Furthermore, it can be performed in the operative room, during the procedure. Therefore, use of 3DRA should allow reduction of dose, contrast-medium and reintervention when compared to technical success assessment with angioCT-scan.

Sponsors

University Hospital, Lille
Lead SponsorOTHER
GE Healthcare
CollaboratorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients treated with EVAR for infra-renal aortic aneurysm * In a hybrid room * With a signed consent

Exclusion criteria

* Pregnant women * Patients unable to understand the study protocol or to give their consents * Renal insufficiency (eGFR\<60mL/min) * Ruptured aneurysms and other emergency settings

Design outcomes

Primary

MeasureTime frameDescription
Effective DoseSingle 1 day - At patient dischargeTotal exposure to radiation in mSv

Secondary

MeasureTime frameDescription
Contrast MediumSingle 1 day - At patient dischargeTotal amount of contrast medium used (mg of Iodine)
Reintervention rateDuring the first 30 daysNumber of secondary procedures due to initial technical issues in both group during the first month
Additional procedureDuring surgeryNumber of additional unplanned procedures during the initial operating time, thanks to complications depicted by respectively the 2D angiography or the 3D rotational angiography.

Countries

France

Contacts

PRINCIPAL_INVESTIGATORStephan Haulon, MD, PhD

University Hospital, Lille

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 6, 2026